Theriva Biologics Reports Promising Trial Results and Financials

Theriva Biologics, Inc. ( (TOVX) ) has released its Q2 earnings. Here is a breakdown of the information Theriva Biologics, Inc. presented to its investors.

Theriva Biologics, Inc. is a clinical-stage company focused on developing therapeutics for cancer and related diseases, leveraging an innovative oncolytic adenovirus platform to enhance cancer treatment efficacy.

In its latest earnings report, Theriva Biologics highlighted significant progress in its clinical trials, particularly with its lead candidate VCN-01, which showed promising results in the Phase 2b VIRAGE trial for metastatic pancreatic cancer. The company also reported a stable financial position with cash reserves expected to support operations into early 2026.

Key financial metrics from the second quarter of 2025 include an increase in general and administrative expenses to $11.2 million, primarily due to contingent consideration adjustments following the successful VIRAGE trial. Research and development expenses decreased to $2.0 million, reflecting lower clinical trial costs. The company reported a net loss of $13.1 million for the quarter, with cash and cash equivalents totaling $12.1 million as of June 30, 2025.

Strategically, Theriva Biologics is preparing for a potential Phase 3 trial for VCN-01 in pancreatic cancer and is expanding its manufacturing capabilities. The company is also exploring partnerships to further advance VCN-01’s development. Additionally, VCN-01 has shown potential in treating retinoblastoma, with Phase 1 data presented at a major oncology conference.

Looking ahead, Theriva Biologics remains focused on advancing its clinical programs and enhancing its manufacturing processes. The management is optimistic about the future prospects of VCN-01 and is committed to addressing unmet medical needs in oncology through innovative therapeutic solutions.